Creso Pharma (ASX:CPH) signs agreement with Swiss food and pharma company Domaco


by Carolyn Herbert

Medicinal cannabis provider Creso Pharma (ASX:CPH) CEO, Dr Miri Halperin Wernli discusses its hemp extract licencing agreement with Domaco, Dr. med. Aufdermaur AG.

The agreement with Domaco is for the development, the manufacture and commercialisation of two new second generation cannabinoid nutraceutical products for use in human health.

Domaco is a traditional Swiss, high tech food and pharma company in business since 1922. It is a leading European producer of innovative products both for global pharmaceutical and global food companies.

The agreement also includes the development of new animal health nutraceutical products for companion animals, with a novel delivery technology.

Creso Pharma will retain all of the IP rights for all of the developed products.  

Carolyn Herbert

Finance News Network
Carolyn joined FNN in August 2015 as the Head of News and also presented the Market at Midday and the Market Wrap. With more than five years of broadcast journalism experience, Carolyn has worked as a finance anchor on the Sky News Business channel and as an anchor and reporter for ABC News. She is also a qualified corporate lawyer specialising in IPOs, takeovers and mergers and acquisitions.